BMXMF:OTC-bioMérieux S.A (USD)

COMMON STOCK | Diagnostics & Research | OTC

Last Closing Price

USD 137.05

Change

-0.04 (-0.03)%

Market Cap

USD 16.10B

Volume

58.00

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that identifies microorganism present in biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as pathological markers. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test, as well as services for clinical and industrial laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Company Website : http://www.biomerieux.com

Address : 376 Chemin De l?Orme, Marcy l'Étoile, France, 69280

Employees : 12,800

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : -0.14

52 Week High : 170.55

52 Week Low : 116.82

200 Day Moving Average : 143.60

50 Day Moving Average : 129.21

Shares Held By Insiders : 687.4%

Shares Held by Institutions : 20.8%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-15 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SMMNY Siemens Healthineers AG

+0.01 (+0.04%)

 USD63.46B 31.48 20.84
RYLPF Koninklijke Philips N.V

+0.91 (+1.51%)

 USD53.98B 38.88 17.97
LZAGF Lonza Group Ltd

+9.00 (+1.49%)

 USD46.46B 48.26 33.18
LZAGY Lonza Group Ltd

+1.13 (+1.88%)

 USD44.27B 47.61 33.18
SSMXF Sysmex Corporation

N/A

 USD21.45B 78.34 0.29
SSMXY Sysmex Corporation

+0.38 (+0.73%)

 USD21.43B 74.83 0.29
ERFSF Eurofins Scientific SE

+1.25 (+1.18%)

 USD19.85B 34.23 16.69
DSRLF DiaSorin S.p.A

-0.75 (-0.41%)

 USD9.89B 33.86 22.67
RTNXF Renalytix AI plc

N/A

 USD0.85B N/A N/A
IDGXF Integrated Diagnostics Holding..

N/A

 USD0.82B 18.81 0.72

ETFs Containing BMXMF

Symbol Name Weight Mer Price(Change) Market Cap
DWMF WisdomTree International .. 0.00 % 0.38 %

+0.20 (+0.76%)

 USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.79% 31% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.79% 31% F 26% F
Trailing 12 Months  
Capital Gain 22.91% 29% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.91% 29% F 31% F
Trailing 5 Years  
Capital Gain 16.89% 40% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.89% 40% F 44% F
Average Annual (5 Year Horizon)  
Capital Gain 11.11% 28% F 56% F
Dividend Return 0.17% 31% F 13% F
Total Return 11.28% 30% F 53% F
Risk Return Profile  
Volatility (Standard Deviation) 46.97% 74% C 47% F
Risk Adjusted Return 24.01% 44% F 53% F
Market Capitalization 16.10B 88% B+ 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 33.75 41% F 25% F
Price/Book Ratio 5.39 63% D 25% F
Price / Cash Flow Ratio 27.62 16% F 8% F
EV/EBITDA 20.84 30% F 20% F
Management Effectiveness  
Return on Equity 17.01% 91% A- 87% B+
Return on Invested Capital 18.79% 74% C 82% B-
Return on Assets 9.93% 96% A 94% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.14 77% C+ 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.